World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
46339
World Ranking
8788
National Ranking
45

Overview

Peter Ferenci is affiliated with the Medical University of Vienna in Austria. Their research focuses predominantly on the field of Medicine, with a substantial number of publications related to Hepatology, Epidemiology, and Nutrition and Dietetics. Additional subfields of interest include Surgery and Health, Toxicology and Mutagenesis.

Their work extensively covers topics such as Liver Disease Diagnosis and Treatment, Hepatitis C virus research, and Liver Disease and Transplantation. Other key research areas include Hepatitis B Virus Studies, Trace Elements in Health, Heavy Metal Exposure and Toxicity, and Liver Diseases and Immunity.

Frequent co-authors collaborating with Peter Ferenci include:

  • Michael Trauner
  • Thomas Reiberger
  • Mattias Mandorfer
  • Albert Friedrich Stättermayer
  • Benedikt Simbrunner

Their publications are often featured in notable medical journals. Frequent publication venues are:

  • Journal of Hepatology
  • Alimentary Pharmacology & Therapeutics
  • Zeitschrift für Gastroenterologie
  • Digestive and Liver Disease
  • JHEP Reports

Among recent papers authored or co-authored by Peter Ferenci are:

  • Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease, 2022, Journal of Hepatology
  • HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease, 2021, Journal of Hepatology
  • Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults, 2020, Journal of Hepatology
  • Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease, 2021, Gastroenterology
  • Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B, 2020, Clinical Infectious Diseases

Best Publications

  • Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

    Ira M. Jacobson;John G. McHutchison;Geoffrey Dusheiko;Adrian M. Di Bisceglie

  • Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

    Peter Ferenci;Alan Lockwood;Kevin Mullen;Ralph Tarter

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

    Hendrik Vilstrup;Piero Amodio;Jasmohan Bajaj;Jasmohan Bajaj;Juan Cordoba

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

    Stefan Zeuzem;Geoffrey M. Dusheiko;Riina Salupere;Alessandra Mangia

  • ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

    Peter Ferenci;David Bernstein;Jacob Lalezari;Daniel Cohen

  • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

    Peter Ferenci;Michael W. Fried;Mitchell L. Shiffman;Coleman I. Smith

  • Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

    Stefan Zeuzem;Maria Buti;Peter Ferenci;Jan Sperl

  • Nature Reviews Disease Primers article: Wilson disease

    Anna Czlonkowska;Tomasz Litwin;Petr Dusek;Peter Ferenci

  • Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy†‡§

    Donald M. Jensen;Timothy R. Morgan;Patrick Marcellin;Paul J. Pockros

  • Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases

    Hendrik Vilstrup;Piero Amodio;Jasmohan Bajaj;Juan Cordoba

  • ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

    Pietro Andreone;Massimo G. Colombo;Jeffrey V. Enejosa;Iftihar Koksal

  • World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

    Douglas R. LaBrecque;Zaigham Abbas;Frank Anania;Peter Ferenci

  • Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.

    Gernot Zollner;Peter Fickert;Rainer Zenz;Andrea Fuchsbichler

  • Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials†

    Naga Chalasani;Cosme Manzarbeitia;Peter Ferenci;Wolfgang Vogel

  • Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study

    Michael W. Fried;Maria Buti;Gregory J. Dore;Robert Flisiak

  • Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

    Mattias Mandorfer;Karin Kozbial;Philipp Schwabl;Clarissa Freissmuth

  • Hepatocellular Carcinoma (HCC): A Global Perspective

    Peter Ferenci;Michael Fried;Douglas Labrecque;Jordi Bruix

  • Experimental models of hepatic encephalopathy: ISHEN guidelines.

    Roger F. Butterworth;Michael D. Norenberg;Vicente Felipo;Peter Ferenci

Frequent Co-Authors

Markus Peck-Radosavljevic
Markus Peck-Radosavljevic Klinikum Klagenfurt
Thomas Reiberger
Thomas Reiberger Medical University of Vienna
Michael Trauner
Michael Trauner Medical University of Vienna
Heidemarie Holzmann
Heidemarie Holzmann Medical University of Vienna
Graham R. Foster
Graham R. Foster Queen Mary University of London
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Ira M. Jacobson
Ira M. Jacobson New York University
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Wolfgang Stremmel
Wolfgang Stremmel Heidelberg University
Patrick Marcellin
Patrick Marcellin Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking flexible learning options, a variety of related online degrees and healthcare career pathways are available. Many students are turning to easiest online dnp programs to advance their nursing credentials while balancing work and personal commitments. These programs offer an efficient route to a Doctor of Nursing Practice, helping working nurses achieve expert status without sacrificing their careers.

For a quicker entry into the healthcare workforce, consider a 9 month lpn program. This accelerated option enables students to become Practical Nurses in under a year, providing a solid foundation for further studies in medicine or allied health.

Those with an interest in mental health can pursue accelerated msn psychiatric np programs, which prepare graduates for essential roles as psychiatric nurse practitioners. These streamlined online programs help meet the growing demand for mental health professionals nationwide.

If you prefer the administrative side of healthcare, an affordable healthcare administration degree online offers a cost-effective and flexible way to develop management expertise. This path can lead to leadership roles within hospitals, clinics, and other healthcare organizations, broadening your potential career trajectory in medicine.

Best Scientists Citing Peter Ferenci

Trending Scientists

Recently Published Articles